Article Details
Retrieved on: 2024-06-04 21:28:52
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca's anti-CTLA-4 antibody with its checkpoint inhibitor reduced the risk of death compared to Nexavar by 22%. Roche's combination showed ...
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here